Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | PAM | P19021 | 2/20 | 0.55 |
| ▸ | CES2 | O00748 | 3/20 | 0.54 |
| ▸ | CES1 | P23141 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.52 |
| ▸ | PPARG | P37231 | 6/20 | 0.52 |
| ▸ | PPARD | Q03181 | 6/20 | 0.52 |
| ▸ | PPARA | Q07869 | 6/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | FABP4 | P15090 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL900152 | 1.00 | DGKA (0.61) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL905880 | 1.00 | DGKA (0.61) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL602197 | 1.00 | DGKA (0.61) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL2980851 | 1.00 | DGKA (0.61) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL426442 | 1.00 | DGKA (0.61) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL337904 | 1.00 | DGKA (0.61) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL262930 | 1.00 | DGKA (0.61) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL394559 | 1.00 | DGKA (0.61) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL8683587 | 1.00 | DGKA (0.61) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL222937 | 1.00 | DGKA (0.61) | DGKALMNAPAMCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1966 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120441751-B | Concrete waterproofing agent and preparation method thereof | NANJING TECH UNIVERSITY (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-116005283-B | Preparation method of degradable aerogel composite functional filament | 山东稀有科技发展有限公司 | 2025-02-07 | — | — | CN | claimed |
| CN-116332665-B | Preparation method of alumina fiber reinforced alumina ceramic matrix composite material containing low-mode interface | 航天特种材料及工艺技术研究所 | 2024-09-24 | — | — | CN | claimed |
| CN-112830849-B | Modified ammonium bicarbonate mixed crystal and preparation method thereof | 四川大学 | 2023-09-26 | — | — | CN | claimed |
| CN-116332665-A | Preparation method of alumina fiber reinforced alumina ceramic matrix composite material containing low-mode interface | 航天特种材料及工艺技术研究所 | 2023-06-27 | — | — | CN | claimed |
| CN-113292785-B | GMT sheet material and preparation method and application thereof | 运研材料科技（上海）有限公司 | 2023-02-03 | — | — | CN | claimed |
| CN-115594385-A | High-temperature high-activity gel breaker for waste slurry treatment | 北京中科润金环保工程股份有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| US-11525078-B2 | Non-toxic high-density fluid for completion applications | TERVES, LLC (US) | 2022-12-13 | — | — | US | claimed |
| CN-113337849-B | Aluminum electrolysis metal ceramic inert anode and near-net-shape preparation method thereof | 中南大学 | 2022-09-30 | — | — | CN | claimed |
| CN-115124395-A | Liquid composite oil phase, preparation method and expanded ammonium nitrate explosive | 河南久联神威民爆器材有限公司 | 2022-09-30 | — | — | CN | claimed |
| WO-2004069225-A1 | NOVEL FLUTICASONE FORMULATIONS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2004-08-19 | — | — | WO | claimed |
| EP-0886551-B1 | STABILITY CONTROL AGENT COMPOSITION FOR POLYOLEFIN FOAM | KNAUS DENNIS A (US) | 2004-08-04 | — | — | EP | claimed |
| WO-2004050059-A1 | LOW VISCOSITY LIQUID DOSAGE FORMS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2004-06-17 | — | — | WO | claimed |
| US-20040105889-A1 | Low viscosity liquid dosage forms | ELAN PHARMA INTERNATIONAL LIMITED | 2004-06-03 | — | — | US | claimed |
| CN-1480134-A | Amino acid iodine composition and preparation method and application thereof | 曾雄飞 | 2004-03-10 | — | — | CN | claimed |
| US-20030185869-A1 | Having lysozyme adsorbed onto or associated with the surface of an active agent | ELAN PHARMA INTERNATIONAL LTD. | 2003-10-02 | — | — | US | claimed |
| WO-2003066021-A2 | DRUG NANOPARTICLES WITH LYSOZYME SURFACE STABILISER | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-08-14 | — | — | WO | claimed |
| US-5484841-A | Method for production of aqueous dispersion of long-chain alkyl graft polymer and aqueous release agent | NIPPON SHOKUBAI KAGAKU KOGYO CO., LTD. (JP) | 1996-01-16 | — | — | US | claimed |
| EP-0298984-A1 | COMPOSITIONS OF LIPOSOMES AND $g(b) 2?-RECEPTOR ACTIVE SUBSTANCES | Aktiebolaget Draco (SE) | 1989-01-18 | — | — | EP | claimed |
| WO-1987005803-A1 | COMPOSITIONS OF LIPOSOMES AND beta2-RECEPTOR ACTIVE SUBSTANCES | AKTIEBOLAGET DRACO (SE) | 1987-10-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030185869-A1 | Having lysozyme adsorbed onto or associated with the surface of an active agent | LPO, LCT, CTSA | DGKA 3754/4885LMNA 430/4885PAM 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.